Basma Abdulhadi

Basma Abdulhadi

Auto-generated profile, based on publicly available information

Basma Abdulhadi

Division of Endocrinology, University of Alabama at Birmingham , Birmingham, AL 35233, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
DCDaniel Gomez Carrillo
Daniel Gomez Carrillo
MKMuhammad Osama Khan
Muhammad Osama Khan
AIAzeem Izhar
Azeem Izhar
HAHameeda Arif Arain
Hameeda Arif Arain
RRRaj Roy
Raj Roy
BABasma Abdulhadi
Basma Abdulhadi
Context: Secondary hyperparathyroidism is a common complication of chronic kidney disease that accelerates bone loss and increases fracture risk. While parathyroidectomy (PTx) is the definitive treatment for medically refractory cases, its impact on bone mineral density (BMD) has not been comprehensively evaluated. Evidence Acquisition: A systematic search of PubMed, Embase, and Scopus was conducted from inception through January 2026. Studies were included if they reported dual-energy X-ray absorptiometry-measured BMD before and after PTx in adults with secondary hyperparathyroidism due to chronic kidney disease. Two reviewers independently screened and selected studies using the Population, Intervention, Comparison, Outcomes, Study Design framework, and additional articles were identified through reference searching. Evidence Synthesis: Across 11 studies encompassing 452 patients with paired measurements, all demonstrated significant improvement in BMD following a site-specific hierarchy favoring cancellous bone. The lumbar spine (+7-50% g/cm2) and femoral neck (+8-23% g/cm2) showed the most consistent gains, while the distal radius showed minimal change. Higher preoperative parathyroid hormone levels, elevated alkaline phosphatase, and lower baseline BMD were associated with greater skeletal recovery. The only available randomized trial confirmed the superiority of PTx over cinacalcet for bone density improvement. Conclusion: PTx consistently improves BMD in patients with refractory secondary hyperparathyroidism, with the greatest gains at cancellous-rich skeletal sites. Clinicians should consider the skeletal benefits of PTx when counseling patients with medically refractory disease, particularly those with low baseline bone density and markedly elevated parathyroid hormone levels.